Sutro Biopharma Inc expected to post a loss of 79 cents a share - Earnings Preview

Sutro Biopharma

06/08/2024 15:06

* Sutro Biopharma Inc  STRO.OQ   STRO.O  is expected to show
a
rise in quarterly revenue when it reports  results on August 8
(estimated) for the period ending June 30 2024
    * The South San Francisco California-based  company is
expected to
report a 101.9% increase in revenue to $21.02 million from
$10.41 million a year ago, according to the mean estimate from
10 analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Sutro Biopharma Inc is
for a
loss of 79 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 10 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had fallen by
about 0.7%
in the last three months. ​
    * Wall Street's median 12-month price target for Sutro
Biopharma
Inc is $11.50​, above​ its last closing price of $3.28. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Mar. 31 2024  -0.88       -0.92      -0.95     Missed  -3
 Jan. 1 2024               -0.82      0.52      Beat    163.2
 Jan. 1 0001   -0.74       -0.74      -0.81     Missed  -10.1​
 Jun. 30 2023  -0.75       -0.73      -0.64     Beat    12.6
 ​​Mar.        -0.80       -0.81      -0.85     Missed  -4.8
 31 2023                                                
 Dec. 31 2022  -0.61       -0.62      -0.68     Missed  -9.5​
 Sep. 30 2022  -0.75       -0.74      -0.37     Beat    49.9
 Jun. 30 2022  -0.43                  -0.55             -19.2
 This summary was machine generated August 6 at 14:06 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)